C. Ola Landgren, MD, PhD, a senior investigator in the Multiple Myeloma Section of the National Cancer Institute, discusses the treatment of older patients (over age 70) with multiple myeloma.
C. Ola Landgren, MD, PhD, a senior investigator in the Multiple Myeloma Section of the National Cancer Institute, discusses the treatment of older patients (over age 70) with multiple myeloma. This interview took place at the 2013 American Society of Hematology (ASH) Meeting.
Clinical Pearls
-Every year in the U.S., 10,000 people under the age of 70 and 10,000 people over the age of 70 are diagnosed with multiple myeloma
-Younger patients typically experience better outcomes while older patients do not see much improvement
@TargetedOncUsing newer therapy strategies, my projection is that#MultipleMyelomapts 70+ yrs will have 2-3x better survival within 5 yrs
Ola Landgren, M.D. (@DrOlaLandgren)April 9, 2014
-Now that older patients are being treated with new drugs, they​ are seeing an improvement in survival
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More